Skip to main content.
Search

Virtus LifeSci Biotech Clinical Trials ETF

Home / ETF / Virtus LifeSci Biotech Clinical Trials ETF
Exchange Traded Fund Domestic Equity

Virtus LifeSci Biotech Clinical Trials ETF

Image specific to each asset class and market style grouping.
Fact Sheet
Ticker
BBC
CUSIP
26923G301
Inception
12/16/2014
NAV
$
(as of 03/01/2021)
Closing Price
$
(as of 03/01/2021)
30-Day Median Bid/Ask Spread
0.20% (as of 03/01/2021)
Premium/Discount
$-0.05 (as of 03/01/2021)
4PM Bid/Offer Midpoint
$56.44 (as of 03/01/2021)
Shares Outstanding
950,004 (as of 03/01/2021)
Daily Trading Volume
13,800.00 (as of 03/01/2021)
20 Day Average Trading Volume
11,280.00 (as of 03/01/2021)
Net Assets
$53,663,741 (as of 03/01/2021)

Portfolio Overview

Investment Overview

The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.

Management Team

Investment Partner

LifeSci Index Partners, LLC

LifeSci Index Partners, LLC is a New York-based index provider of healthcare-based stock market indices. The LifeSci team is comprised of investment professionals with experience in biotechnology equity research, in organic chemistry research in academia, and at pharmaceutical and biotechnology companies.

LifeSci Index Partners, LLC is the index provider to the Fund. The portfolio managers are affiliated with Virtus ETF Advisers, LLC, the Fund's adviser.


Investment Professionals

Matthew Brown

Matthew B. Brown

Chief Operating Officer and Portfolio Manager, Virtus ETF Advisers LLC

Industry start date: 1999
Start date as fund Portfolio Manager: 2017

Show More
Seth Kadushin

Seth Kadushin

Portfolio Manager, Virtus ETF Advisers LLC

Industry start date: 1988
Start date as fund Portfolio Manager: 2017

Show More

Key Features

High-Growth Potential

One of the most dynamic stock sectors, covering companies that design drugs, from entrepreneurial start-ups to global giants

Pure, Targeted Exposure

Passively invests solely in firms with promising drugs in clinical human trials that have not yet been approved by the FDA or gone into production

Equally Weighted

Equal stock weightings, at the time of semi-annual index rebalance, help ensure even relatively small firms with major breakthroughs can have meaningful impacts on returns

Positions & Distributions

Top Holdings (% Fund)

(as of 03/02/2021)
Security
AMYRIS INC
2.69
 2.69
NANTKWEST INC
1.60
 1.60
MORPHIC HOLDING INC
1.41
 1.41
VIR BIOTECHNOLOGY INC
1.15
 1.15
NOVAVAX INC
1.03
 1.03
APPLIED MOLECULAR TRANSPORT
0.99
 0.99
DYNAVAX TECHNOLOGIES CORP
0.96
 0.96
ZIOPHARM ONCOLOGY INC
0.95
 0.95
PROTHENA CORP PLC
0.95
 0.95
I-MAB-SPONSORED ADR
0.94
 0.94

Does not include cash/cash equivalents.

Performance & Risk

Performance

As of
As of

Performance data quoted represents past results. Past performance is no guarantee of future results and current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate, so your shares, when redeemed, may be worth more or less than their original cost.

Sales Charge and Expenses

The Total Expense Ratio represents the Fund's Total Annual Fund Operating Expenses, which includes the management fee and other expenses where applicable, except for certain payments that are paid directly by the Fund, as described in the Prospectus.

Fees & Expenses

Total Expense Ratio 0.79
The Total Expense Ratio represents the Fund's Total Annual Fund Operating Expenses, which includes the management fee and other expenses where applicable, except for certain payments that are paid directly by the Fund, as described in the Prospectus.


Number of Days Fund has Traded at a:
Discount Premium
Period Less than -2% -1.51% to -2.00% -1.01% to -1.50% -0.51% to -1.00% -0.01% to -0.50% 0.00% to 0.50% 0.51% to 1.00% 1.01% to 1.50% 1.51% to 2.00% Greater than 2%
2019-Q1: 1/2/2019 through 3/29/2019 0 0 0 0 53 8 0 0 0 0
2019-Q2: 4/1/2019 through 6/28/2019 0 0 0 0 61 2 0 0 0 0
2019-Q3: 7/1/2019 through 9/30/2019 0 0 0 0 61 3 0 0 0 0
2019-Q4: 10/1/2019 through 12/31/2019 0 0 0 0 48 16 0 0 0 0
2020-Q1: 1/2/2020 through 3/31/2020 0 1 0 2 41 18 0 0 0 0
2020-Q2: 4/1/2020 through 6/30/2020 0 0 0 0 34 29 0 0 0 0
2020-Q3: 7/1/2020 through 9/30/2020 0 0 0 0 41 23 0 0 0 0
2020-Q4: 10/1/2020 through 12/31/2020 0 0 0 0 52 12 0 0 0 0

Risk Considerations

Exchange-Traded Funds (ETF): The value of an ETF may be more volatile than the underlying portfolio of securities it is designed to track. The costs to the fund of owning shares of an ETF may exceed the cost of investing directly in the underlying securities.
Equity Securities: The market price of equity securities may be adversely affected by financial market, industry, or issuer-specific events. Focus on a particular style or on small or medium-sized companies may enhance that risk.
Industry/Sector Concentration: A fund that focuses its investments in a particular industry or sector will be more sensitive to conditions that affect that industry or sector than a non-concentrated fund.
Passive Strategy/Index Risk: A passive investment strategy seeking to track the performance of the underlying Index may result in the fund holding securities regardless of market conditions or their current or projected performance. This could cause the fund's returns to be lower than if the fund employed an active strategy.
Correlation to Index: The performance of the fund and its index may vary due to factors such as fund flows, transaction costs, whether the fund obtains every security in the index, and timing differences associated with additions to and deletions from its index.
Market Price/NAV: At the time of purchase and/or sale, an investor's shares may have a market price that is above or below the fund's NAV, which may increase the investor's risk of loss.
Market Volatility: Local, regional, or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, recessions, or other events could have a significant impact on the portfolio and its investments, including hampering the ability of the portfolio manager(s) to invest the portfolio's assets as intended.
Prospectus: For additional information on risks, please see the fund's prospectus.

Documents & Resources

Marketing Materials

Virtus LifeSci Biotech Clinical Trails ETF Fact Sheet (BBC)
Download
Virtus LifeSci Biotech ETF Commentary (BBC and BBP)
Download
Virtus ETF Ticker Menu
Download
Two Unique Ways to Play Biotech via Specialized ETFs
Download

Holdings

Positions BBC
Download

Financial Materials

BBP and BBC Prospectus - Feb. 28, 2020
Download
ETFis Series Trust I XBRL 497
Download
ETFis Series Trust I XBRL 485(b)
Download
BBP and BBC SAI - Feb. 2020
Download
ETFis Series Trust I Annual Report - Oct 2020
Download
ETFis Series Trust I Semi-Annual Report - April 2020
Download

Please consider the investment objectives, risks, charges and expenses of the Fund carefully before investing. The prospectus contains this and other information about the Fund. Contact us at 1-888-383-0553 or visit www.virtus.com for a copy of the Fund's prospectus. Read the prospectus carefully before you invest or send money.

Performance data quoted represents past results. Past performance is no guarantee of future results and current performance may be higher or lower than the performance shown. Investment return and principal value will fluctuate so your shares, when redeemed, may be worth more or less than their original cost.

Closing Price: The Closing Price is the price of the last reported trade on the fund's primary exchange. If there has been no reported trade for a particular date, the Closing Price represents the 4PM Bid/Offer Midpoint. 

4PM Bid/Offer Midpoint: The midpoint between the highest bid and the lowest offer on the listing exchange, as of the time that the Fund's NAV is calculated (usually 4:00pm Eastern Time).

Premium/Discount: The amount the Fund is trading above or below the reported NAV (based on 4PM Bid/Offer Midpoint).

The Fund is an exchange-traded fund (“ETF”). The “net asset value” (NAV) of the Fund is determined at the close of each business day, and represents the dollar value of one share of the Fund; it is calculated by taking the total assets of the Fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV of the Fund is not necessarily the same as its intraday trading value. Fund investors should not expect to buy or sell shares at NAV because shares of ETFs such as the Fund are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Thus, shares may trade at a premium or discount to their NAV in the secondary market. Brokerage commissions will reduce returns.

NAV returns are calculated using the Fund’s daily 4:00 p.m. NAV, and include the reinvestment of all dividends and other distributions (reinvested at the Fund's NAV on distribution ex-date). Market price returns are calculated using the 4:00 pm midpoint between the bid and offer, and include the reinvestment of all dividends and other distributions (reinvested at the 4:00pm bid/offer midpoint on distribution ex-date). Market price returns do not represent the return you would receive if you traded at other times.

Returns for periods of less than one year are cumulative total returns.

Not insured by FDIC/NCUSIF or any federal government agency. No bank guarantee. Not a deposit. May lose value.